Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
October 27, 2018 10:09 ET | Source: Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in… Read More »
- Posted on: Oct 28 2018